The Readout

Moderna’s patent problems & clocking the CRISPR race

By Damian Garde @damiangarde and Meghana Keshavan @megkesh

May 17, 2017

Alex Hogan/STAT

The Readout for May 17, 2017

About the Authors

Damian Garde
National Biotech Reporter
Damian covers biotech and writes The Readout newsletter.
Meghana Keshavan
Biotech Correspondent
Meghana covers biotech and writes The Readout newsletter.
Trending
CCoA Screen Shot
Cancer centers sell out science when they advertise clinical…
Cancer centers sell out science when they advertise clinical trials as treatment
FDA-Blood Sugar Monitor
FDA approves first blood sugar monitor without finger pricks
FDA approves first blood sugar monitor without finger pricks
Heroin and Fentanyl doses
Why fentanyl is deadlier than heroin, in a single…
Why fentanyl is deadlier than heroin, in a single photo
Recommended
The READOUT
Amgen’s stagnancy & Biogen’s existential questions
Amgen’s stagnancy & Biogen’s existential questions
The READOUT
Woodford’s (latest) mea culpa & Incyte’s (other) big binary
Woodford’s (latest) mea culpa & Incyte’s (other) big binary
The READOUT
Holding out hope for combination immunotherapy & PhRMA lobbies…
Holding out hope for combination immunotherapy & PhRMA lobbies hard

Recommended Stories

The READOUT
The Readout

Amgen’s stagnancy & Biogen’s existential questions

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

Woodford’s (latest) mea culpa & Incyte’s (other) big binary

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

Holding out hope for combination immunotherapy & PhRMA lobbies hard

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

Novartis’ meek CAR-T sales & tinkering with epigenetics

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

A reprieve on drug ads & Gilead’s supreme clientele

By Damian Garde and Meghana Keshavan

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.